Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
395 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT04376931 | A Prospective Dose Finding Study of Iscador Infusion | unknown | Phase 1 / Phase 2 | 24 | HaEmek Medical Center, IsraelOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02261220 | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 380 | MedImmune LLCINDUSTRY | 9 | Mar 6, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT03052205 | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors(ILLUMINATE-101) | completed | Phase 1 | 54 | Idera Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 11, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02828878 | Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT04147182 | Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection | unknown | Phase 1 | 15 | Dan LeiboviciOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT01861509 | BP-C1 in Metastatic Breast Cancer Patients | completed | Phase 1 | 10 | Meabco A/SINDUSTRY | 2 | Oct 7, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT02518113 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | completed | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 11, 2019 | clinicaltrials |
| NCT02848911 | Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL | terminated | Phase 1 | 17 | Affimed GmbHINDUSTRY | 5 | Jun 19, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03099161 | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jun 5, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00711997 | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 9 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Mar 20, 2019 | clinicaltrials |
| NCT01878188 | Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma | completed | Phase 1 | 38 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01705002 | Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | completed | Phase 1 | 88 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01690741 | Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies | completed | Phase 1 | 23 | Immune System Key LtdINDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT01767623 | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | completed | Phase 1 | 8 | Hoffmann-La RocheINDUSTRY | 7 | Feb 13, 2018 | clinicaltrials |
| NCT00169533 | Rollover Study Of Lapatinib In Cancer Patients | completed | Phase 1 | 31 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00359190 | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT02149459 | Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy(SMC 0712-13) | unknown | Phase 1 | 18 | Sheba Medical CenterOTHER_GOV | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01764880 | SST0001 (Roneparstat) in Advanced Multiple Myeloma | completed | Phase 1 | 19 | Sigma Tau Research Switzerland SAINDUSTRY | 3 | Oct 23, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02052492 | Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | Efranat Ltd.INDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT00825682 | The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Sheba Medical CenterOTHER_GOV | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02442063 | Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | completed | Phase 1 | 15 | BayerINDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT00906113 | Intra-arterial Chemotherapy for Children With Retinoblastoma | unknown | Phase 1 / Phase 2 | 10 | Hadassah Medical OrganizationOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00261365 | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) | completed | Phase 1 / Phase 2 | 80 | Bristol-Myers SquibbINDUSTRY | 7 | Sep 29, 2016 | clinicaltrials |
| NCT02908607 | Thermal Imaging for Evaluation of the Cervix | unknown | Phase 1 / Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Sep 21, 2016 | clinicaltrials |
| NCT01952769 | Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | unknown | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT02115672 | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 / Phase 2 | 43 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 12 | May 23, 2016 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials